Horizon Discovery (HZD LN)

Horizon Discovery Group plc, a life science company, designs and engineers genetically-modified cells and applies them in research and clinical applications to advance human health worldwide. Its core capabilities are built around its proprietary transnational genomics platform, a suite of gene editing tools, such as rAAV, ZFN, and CRISPR to alter almost any gene sequence in human or mammalian cell-lines. The company offers approximately 23,000 catalog products and related research services, based on the generation and application of cell and in vivo models that recapitulate the disease-causing genetic anomalies found in diseases like cancer. The company is involved in the engineering of in-vitro and in-vivo disease modules; use of in-vitro and in-vivo disease modules in drug discovery and development; development of cell lines for manufacturing biologic drugs; and development of cell-derived molecular reference standards for clinical labs. It provides independent external controls to routinely monitor the performance of workflows and assays; gene-editing, isogenic cell line assays, screening platforms, and in-vivo models to help solve research and drug development challenges; products and services for the production of molecule therapeutics, offering solutions for organizations of various sizes; and genetically-defined isogenic cell lines and in-vivo research models. It serves pharmaceutical, biotechnology, and diagnostics companies, as well as academic research centers. Horizon Discovery Group plc was founded in 2005 and is headquartered in Cambridge, the United Kingdom.